V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

Muller, Stéphanie; Lai, W. Victoria; Adusumilli, Prasad S.; Desmeules, Patrice; Frosina, Denise; Jungbluth, Achim A.; Ni, Ai; Eguchi, Takashi; Travis, William D.; Ladanyi, Marc; Zauderer, Marjorie G.; Sauter, Jennifer L.

doi:10.1038/s41379-019-0364-z

Cited by 73 publications

(63 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, 299 duplicate publications were excluded, and 153 studies were screened by title and abstract. Subsequently, 119 studies were discarded and 34 studies 9 , 18 – 23 , 27 – 53 were left for eligibility assessment by full-text examination. Eighteen studies were excluded for different reasons: one study did not detect PD-L1 expression in sera samples other than tumor tissues, 37 11 studies did not present sufficient data for meta-analysis, 9 , 38 , 39 , 42 – 48 , 52 two studies did not use unique cut-off value, 40 , 50 one study did not test PD-L1 expression, 41 one study was a letter to the editor, 49 and two studies recruited patients with pleural and peritoneal mesothelioma tumors other than MPM.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Jin¹,

Xie³

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 51 , 53 Finally, 16 studies were included in our meta-analysis. 18 – 23 , 27 – 36 The flow chart of the article screening process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Jin¹,

Xie³

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…High expression of VISTA in solid tumours is associated with favourable OS. Seven studies 6,7,[11][12][13] reported the relationship between the expression of VISTA and patients' OS. We applied a fixed effect model to calculate the pooled hazard ratio (HR) and 95% confidence interval (CI) because there was no obvious heterogeneity (P = 0.564, I 2 = 0.0%).…”

Section: Characteristics Of the Included Studies As Presented Inmentioning

confidence: 99%

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Multiple immune checkpoints molecules have been known to be able to inhibit the function of CD8+ T cells by sending negative regulatory signals. Some of these molecules are Cytotoxic T-lymphocyte antigen 4 (CTLA-4/ CD152), Programmed cell death protein 1 (PD-1/ CD279), Lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and mucin domain 3 (TIM-3), and V-domain immunoglobulin suppressor of T cell activation (VISTA) [ 38 , 39 , 40 ]. Generally these immunosuppressive molecules work by exhausting the CD4+ and CD8+ T infiltrating lymphocytes; promoting T regulatory differentiation; abrogating the CD8+ cytotoxic effect; downregulating T cell proliferation; and all those effects culminating in enhancing immune tolerance [ 38 , 39 ].…”

Section: Immune Checkpoint Inhibitionmentioning

confidence: 99%

Tackling Resistance to Cancer Immunotherapy: What Do We Know?

et al. 2020

View full text Add to dashboard Cite

Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward.

show abstract

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

Cited by 73 publications

References 38 publications

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Tackling Resistance to Cancer Immunotherapy: What Do We Know?

Contact Info

Product

Resources

About